NEW YORK ( TheStreet) -- CHANGE IN RATINGS:
downgraded at JP Morgan FEB 06, 2013 | 7:45 AM EST ACI was downgraded to neutral, JP Morgan said. Company has high financial leverage.
(AGN - Get Report)
upgraded at JMP from market perform to Outperform, JMP Securities said. $135 price target. Company is seeing higher demand for Botox.
downgraded at Keybanc from hold to underweight, Keybanc said. $54 price target. Valuation call, as the stock is up 48% since mid-2012.
downgraded at BofA/Merrill from buy to underperform, Bank of America/Merrill Lynch said. $60 price target. Company will struggle to meet its long-term growth targets.
upgraded at Citigroup to neutral from sell, Citigroup said. $13.65 price target. High likelihood of deal completion.
upgraded at Sterne Agee from neutral to buy, Sterne Agee said. $22 price target. Investor focus is shifting toward the next console cycle.
upgraded at JP Morgan to overweight, JP Morgan said. Trends are stabilizing and the company is facing easier comparisons.
(FL - Get Report)
rated new outperform at Baird. $45 price target. Strong basketball shoe trends will likely drive near-term growth.
rated new buy at Citigroup. $41 price target. Gaining exposure in sustainable growth regions.
upgraded at Citigroup to buy from neutral, Citigroup said. $22 price target. Unappreciated near term catalysts.
downgraded at BofA/Merrill to neutral, Bank of America/Merrill Lynch said. $24 price target. Valuation call, as the stock is up 22% over the past two months.
Marsh & McLennan
(MMC - Get Report)
upgraded at Goldman from neutral to buy, Goldman Sachs said. $40 price target. Pricing trends are improving and the stock has lagged its peers.
downgraded at JP Morgan from overweight to neutral, JP Morgan said. Valuation call, as the stock gained 41% last year.
downgraded at Citigroup to neutral from buy, Citigroup said. $49 price target. High quality franchise, but fairly valued.
(SPWR - Get Report)
rated new buy at Citigroup. $12 price target. Industry leading efficiency panels.